Impaired release of tissue plasminogen activator from the endothelium in Graves' disease — indicator of endothelial dysfunction and reduced fibrinolytic capacity

Li, Y; Chen, H; Tan, Josephine M.E.; Wang, X; Liang, Hsin‐Yueh; Sun, Xiaohong

doi:10.1046/j.1365-2362.1998.00381.x

Cited by 46 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, increased levels of PAI-1 antigen have been reported in patients with both thyroid dysfunctions [20,22]. Results from the few studies evaluating PAI-1 levels in hyperthyroid patients suggest that PAI-1 is elevated in hyperthyroidism [8][9][10]20]. We found lower TAFI and elevated PAI-1 antigen levels in patients with hyperthyroidism.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels Are Inversely Correlated with Plasminogen Activator Inhibitor-1 Antigen Levels in Hyperthyroid Patients

et al. 2007

View full text Add to dashboard Cite

Abstract. Both increased and decreased fibrinolytic activity have been reported in patients with hyperthyroidism. Elevated levels of plasma plasminogen activator inhibitor-1 (PAI-1) antigen have been found in hyperthyroid patients. Thrombin activatable fibrinolysis inhibitor (TAFI) is a novel plasma protein, which inhibits fibrinolysis through removal of C-terminal lysines from partially degraded fibrin. Previously, we showed that plasma TAFI antigen levels were increased in patients with overt and subclinical hypothyroidism. The aim of this study is to investigate plasma levels of TAFI and PAI-1 antigens in hyperthyroid patients. PAI-1 and TAFI antigen levels were measured in the plasma of 29 patients with hyperthyroidism (14 overt hyperthyroid and 15 subclinical hyperthyroid), and 26 healthy individuals. Although there were increased levels of PAI-1 antigen in hyperthyroid patients, plasma TAFI antigen levels were significantly lower compared to controls (80.79 ng/ml vs. 32.42 ng/ml, p = 0.000 for PAI-1; 10.42 µg/ml vs. 12.24 µg/ml, p = 0.009 for TAFI). Elevated PAI-1 antigen levels were positively correlated with free thyroid hormones, although TAFI antigen levels were in negative correlation with free thyroxine. Furthermore, an inverse correlation between PAI-1 and TAFI antigen levels was found. Our study demonstrated that TAFI antigen levels were decreased in patients with hyperthyroidism. Inverse correlation with PAI-1 suggests that the decrease in TAFI antigen levels may be due to activation of TAFI pathway. Further studies evaluating the underlying mechanisms of low TAFI antigen levels in hyperthyroidism should be undertaken.

show abstract

Section: Discussionsupporting

confidence: 77%

“…Dorr and Volzke [8] showed that decreased serum TSH is an independent risk factor for elevated plasma fibrinogen levels. Li et al [9] reported that serum thyroid hormone concentrations were strongly correlated with plasma PAI-1. Ozcan et al [10] found that elevated PAI-1 antigen levels in hyperthyroid patients decreased after euthyroidism was restored.…”

mentioning

confidence: 99%

Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels Are Inversely Correlated with Plasminogen Activator Inhibitor-1 Antigen Levels in Hyperthyroid Patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Except in one study (22), no effect of thyroid status on serum levels of TNF-a has been demonstrated (23)(24)(25)(26). Only a few studies on serum PAI-1 levels have been presented showing an increased level in hyperthyroidism (27) and a decreased level in severe hypothyroidism (28). Taken together with the data on both serum and adipose tissue secretion concentrations in this study, it can be concluded that thyroid status, at least in the case of hyperthyroidism, plays a minor role in the hormonal regulation of leptin and TNF-a.…”

Section: Discussionmentioning

confidence: 93%

Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism

Wahrenberg

Wennlund

Hoffstedt

2002

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: This study was designed to investigate adipose tissue secretion of interleukin-6 (IL-6), leptin, tumour necrosis factor alpha (TNF-a) and plasminogen activator inhibitor-1 (PAI-1) in Graves' hyperthyroidism. Design: We studied 10 patients before and during (after 8 weeks) anti-thyroid treatment for Graves' hyperthyroidism and 16 healthy, euthyroid control subjects. Methods: Plasma levels of thyroid hormones and serum/plasma levels of IL-6, leptin, TNF-a and PAI-1 were analysed. Subcutaneous fat biopsies were taken for subsequent measurement of IL-6, leptin, TNF-a and PAI-1 protein secretion. Results: In patients with Graves' disease, the anti-thyroid treatment resulted in significant reductions of plasma thyroxine and triiodothyronine levels. No differences in serum concentration or adipose tissue secretion of leptin or TNF-a were observed either before, as compared with during, anti-thyroid treatment, or in comparison with euthyroid controls. In contrast, plasma PAI-1 activity, but not adipose tissue secretion of PAI-1, was increased both in Graves' disease before as compared with during anti-thyroid treatment ðP ¼ 0:01Þ and in thyrotoxic patients compared with euthyroid controls ðP ¼ 0:0001Þ: Finally, adipose secretion of IL-6 was increased both before (8-fold, P ¼ 0:001) and during (6-fold, P , 0:0001) treatment as compared with control subjects. Accordingly, serum concentration of IL-6 was also increased by about 50% in thyrotoxic patients as compared with healthy controls ðP ¼ 0:03Þ: Conclusions: In Graves' hyperthyroidism regardless of thyroid status, adipose tissue secretion of IL-6, but not of leptin, TNF-a or PAI-1, is markedly increased in comparison with euthyroid controls. This suggests that autoimmune thyroidal disorder may regulate adipose tissue release of IL-6.

show abstract

“…Some reports have described an increase in serum PAI-1 concentration in hyperthyroidism, whereas others did not detect any differences (7)(8)(9).…”

Section: Introductionmentioning

confidence: 89%

The effect of thyroid hormones on the white adipose tissue gene expression of PAI-1 and its serum concentration

Biz

Oliveira

Mattos

et al. 2009

Braz J Med Biol Res

View full text Add to dashboard Cite

Impaired release of tissue plasminogen activator from the endothelium in Graves' disease — indicator of endothelial dysfunction and reduced fibrinolytic capacity

Abstract: Hyperthyroid patients may experience vascular endothelial dysfunction and reduced fibrinolytic activity in blood.

Cited by 46 publications

References 24 publications

Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels Are Inversely Correlated with Plasminogen Activator Inhibitor-1 Antigen Levels in Hyperthyroid Patients

Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels Are Inversely Correlated with Plasminogen Activator Inhibitor-1 Antigen Levels in Hyperthyroid Patients

Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism

The effect of thyroid hormones on the white adipose tissue gene expression of PAI-1 and its serum concentration

Contact Info

Product

Resources

About